Pain from skeletal metastases represents a major burden of advanced disease from solid tumors. Analgesic medications, bisphosphonates, hormonal agents, cytotoxic chemotherapy, and external beam radiotherapy are all effective treatments. However, patients often suffer from diffuse painful metastases and respond poorly to these standard therapies. Bone-seeking radionuclides can specifically target osteoblastic lesions to offer palliation of pain.
Methods
This article offers a narrative review of bone-seeking radionuclides, examines the evidence of safety and efficacy for the treatment of painful skeletal metastases, and presents guidelines for their appropriate use in this patient population.
Results
Seven bone-seeking radionuclides have shown evidence of both safety and efficacy in reducing pain from diffuse skeletal metastases. 153Sm-EDTMP and 89Sr are most commonly used in the United States and have been safely utilized for both repeat dosing as well as concurrent dosing with cytotoxic chemotherapy.
Conclusions
Targeted bone-seeking radionuclides are underutilized in the treatment of painful diffuse osteoblastic metastases. Several new agents are in active clinical investigation, and the pending approval of the first alpha-emitting radionuclide (223Ra) may offer a new class of agents that provide greater efficacy and less toxicity than those currently available for routine clinical use.
References
1.
PaesF.M., SerafiniA.N.. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain.Semin Nucl Med.2010; 40(2): 89–104.
2.
SolowayM.S., HardemanS.W., HickeyD.. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.Cancer.1988; 61(1): 195–202.
StollB.A.. Natural history, prognosis, and staging of bone metastases. In: SzollB.A., ParbooS., eds. Bone Metastases: Monitoring and Treatment.New York, NY: Raven; 1983: 1–20.
5.
MuirG.H., ButtaA., ShearerR.J.. Induction of transforming growth factor beta in hormonally treated human prostate cancer.Br J Cancer.1994; 69(1): 130–134.
6.
KostenuikP.J., SinghG., OrrF.W.. Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen.Clin Exp Metastasis.1997; 15(1): 41–52.
7.
RajanR., VandersliceR., KapurS.. Epidermal growth factor (EGF) promotes chemomigration of a human prostatic tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone.Prostate.1996; 28(1): 1–9.
8.
LudwigH., KumpanW., SinzingerH.. Radiography and bone scintigraphy in multiple myeloma: a comparative analysis.Br J Radiol.1982; 55(651): 173–181.
9.
HorvatA.G., KovačV., StrojanP.. Radiotherapy in palliative treatment of painful bone metastases.Radiol Oncol.2009; 43(4): 213–224.
10.
PortenoyR.K., PayneD., JacobsenP.. Breakthrough pain: characteristics and impact in patients with cancer pain.Pain.1999; 81(1-2): 129–134.
11.
LutzS., BerkL., ChangE.. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline.Int J Radiat Oncol Biol Phys.2011; 79(4): 965–976.
12.
TongD., GillickL., HendricksonF.R.. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group.Cancer.1982; 50(5): 893–899.
13.
PoulterC.A., CosmatosD., RubinP.. A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases.Int J Radiat Oncol Biol Phys.1992; 23(1): 207–214.
14.
KubanD.A., DelbridgeT., el-MahdiA.M.. Half-body irradiation for treatment of widely metastatic adenocarcinoma of the prostate.J Urol.1989; 141(3): 572–574.
15.
International Commission on Radiation Units and Measurements.Stopping powers for electrons and positrons. ICRU Report 37. Bethesda, MD: International Commission on Radiation Units and Measurements; 1984.
16.
SilbersteinE.B.. The treatment of painful osseous metastases with phosphorus-32-labeled phosphates.Semin Oncol.1993; 20(3 suppl 2): 0–21.
17.
HenriksenG., FisherD.R., RoeskeJ.C.. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.J Nucl Med.2003; 44(2): 252–259.
18.
TaylorAJJr. Strontium-89 for the palliation of bone pain due to metastatic disease.J Nucl Med.1994; 35(12): 2054.
19.
BlakeG.M., ZivanovicM.A., BlaquiereR.M.. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.J Nucl Med.1988; 29(4): 549–557.
20.
FusterD., HerranzD., Vidal-SicartS.. Usefulness of stron-tium-89 for bone pain palliation in metastatic breast cancer patients.Nucl Med Commun.2000; 21(7): 623–626.
21.
Kraeber-BodéréF., CampionL., RousseauC.. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement.Eur J Nucl Med.2000; 27(10): 1487–1493.
22.
AshayeriE., OmogbehinA., SridharR.. Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience.J Natl Med Assoc.2002; 94(8): 706–711.
23.
GunawardanaD.H., LichtensteinM., BetterN.. Results of stron-tium-89 therapy in patients with prostate cancer resistant to chemotherapy.Clin Nucl Med.2004; 29(2): 81–85.
24.
LiepeK., KotzerkeJ.. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.Nucl Med Commun.2007; 28(8): 623–630.
25.
TurnerS.L., GruenewaldS., SpryN.Metastron Users Group. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer.Br J Cancer.2001; 84(3): 297–302.
26.
MertensW.C., StittL., PorterA.T.. Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship?Am J Clin Oncol.1993; 16(3): 238–242.
27.
PorterA.T., McEwanA.J., PoweJ.E.. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.Int J Radiat Oncol Biol Phys.1993; 25(5): 805–813.
28.
SciutoR., MainiC.L., TofaniA.. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89.Nucl Med Commun.1996; 17(9): 799–804.
29.
SciutoR., FestaA., ReaS.. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.J Nucl Med.2002; 43(1): 79–86.
30.
TuS.M., MillikanR.E., MengistuB.. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.Lancet.2001; 357(9253): 336–341.
31.
OosterhofG.O., RobertsJ.T., de ReijkeT.M.. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.Eur Urol.2003; 44(5): 519–526.
32.
QuiltyP.M., KirkD., BolgerJ.J.. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.Radiother Oncol.1994; 31(1): 33–40.
33.
GoeckelerW.F., TroutnerD.E., VolkertW.A.. 153Sm radiothera-peutic bone agents.Int J Rad Appl Instrum B.1986; 13(4): 479–482.
34.
PaesF.M., ErnaniV., HoseinP.. Radiopharmaceuticals: when and how to use them to treat metastatic bone pain.J Support Oncol.2011; 9(6): 197–205.
35.
SinghA., HolmesR.A., FarhangiM.. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer.J Nucl Med.1989; 30(11): 1814–1818.
DolezalJ.. Systemic radionuclide therapy with samarium-153-EDTMP for painful bone metastases.Nucl Med Rev Cent East Eur.2000; 3(2): 161–163.
38.
DolezalJ., VizdaJ., OdrazkaK.. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.Urol Int.2007; 78(1): 50–57.
39.
TianJ.H., ZhangJ.M., HouQ.T.. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.Eur J Nucl Med.1999; 26(1): 2–7.
40.
EtchebehereE.C., Pereira NetoC.A., LimaM.C.. Treatment of bone pain secondary to metastases using samarium-153-EDTMP.Sao Paulo Med J.2004; 122(5): 208–212.
41.
SapienzaM.T., OnoC.R., GuimarãesM.I.. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.Rev Hosp Clin Fac Med Sao Paulo.2004; 59(6): 321–328.
42.
CollinsC., EaryJ.F., DonaldsonG.. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial.J Nucl Med.1993; 34(11): 1839–1844.
43.
RescheI., ChatalJ.F., PeckingA.. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.Eur J Cancer.1997; 33(10): 1583–1591.
44.
SerafiniA.N., HoustonS.J., RescheI.. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.J Clin Oncol.1998; 16(4): 1574–1581.
45.
SartorO., ReidR.H., HoskinP.J.. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.Urology.2004; 63(5): 940–945.
46.
SartorO., ReidR.H., BushnellD.L.. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.Cancer.2007; 109(3): 637–643.
47.
MendaY., BushnellD.L., WilliamsR.D.. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain.Clin Nucl Med.2000; 25(9): 698–700.
48.
MorrisM.J., Pandit-TaskarN., CarrasquilloJ.. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.J Clin Oncol.2009; 27(15): 2436–2442.
49.
TuS.M., MathewP., WongF.C.. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.J Clin Oncol.2009; 27(20): 3319–3324.
50.
FizaziK., BeuzebocP., LumbrosoJ.. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.J Clin Oncol.2009; 27(15): 2429–2435.
51.
FinlayI.G., MasonM.D., ShelleyM.. Radioisotopes for the palliation of metastatic bone cancer: a systematic review.Lancet Oncol.2005; 6(6): 392–400.
52.
De KlerkJ.M., ZonnenbergB.A., BlijhamG.H.. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.Anticancer Res.1997; 17(3B): 1773–1777.
53.
SciutoR., FestaA., PasqualoniR.. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.Breast Cancer Res Treat.2001; 66(2): 101–109.
54.
DafermouA., ColamussiP., GigantiM.. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.Eur J Nucl Med.2001; 28(7): 788–798.
55.
de KlerkJ.M., van het SchipA.D., ZonnenbergB.A.. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.J Nucl Med.1996; 37(2): 244–249.
56.
HanS.H., de KlerkJ.M., TanS.. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186) Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.J Nucl Med.2002; 43(9): 1150–1156.
57.
EnglaroE.E., SchroderL.E., ThomasS.R.. Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases: initial case reports of two patients.Clin Nucl Med.1992; 17(1): 41–44.
58.
PalmedoH., GuhlkeS., BenderH.. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases.Eur J Nucl Med.2000; 27(2): 123–130.
59.
PalmedoH., Manka-WaluchA., AlbersP.. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.J Clin Oncol.2003; 21(15): 2869–2875.
60.
LewingtonV.J.. Bone-seeking radionuclides for therapy.J Nucl Med.2005; 46(suppl 1): 38S–47S.
61.
KrishnamurthyG.T., SwailemF.M., SrivastavaS.C.. Tin-117m(4+) DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain.J Nucl Med.1997; 38(2): 230–237.
62.
BouchetL.G., BolchW.E., GodduS.M.. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions.J Nucl Med.2000; 41(4): 682–687.
63.
SrivastavaS.C., AtkinsH.L., KrishnamurthyG.T.. Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study.Clin Cancer Res.1998; 4(1): 61–68.
64.
AtkinsH.L., MausnerL.F., SrivastavaS.C.. Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study.J Nucl Med.1995; 36(5): 725–729.
65.
NilssonS., LarsenR.H., FossåS.D.. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.Clin Cancer Res.2005; 11(12): 4451–4459.
66.
NilssonS., FranzénL., ParkerC.. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.Lancet Oncol.2007; 8(7): 587–594.
67.
ParkerC., HeinrichD., O'SullivanJ.M.. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomised trial (ALSYMPCA). Presented at the European Multidisciplinary Cancer Congress; September 23 - 27, 2011; Stockholm, Sweden. Abstract 1LBA.
68.
ChakrabortyS., DasT., BanerjeeS.. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis.Cancer Biother Radiopharm.2008; 23(2): 202–213.
69.
MáthéD., BaloghL., PolyákA.. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent.Nucl Med Biol.2010; 37(2): 215–226.
70.
LiuC., BrasicJ.R., LiuX.. Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone palliation treatment.Nucl Med Commun.2012; 33(1): 90–96.
71.
DasT., ChakrabortyS., SarmaH.D.. (170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation.Nucl Med Biol.2009; 36(5): 561–568.
72.
BaczykM., CzepczyńskiR., MileckiP.. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma.Nucl Med Commun.2007; 28(4): 245–250.
73.
ChristensenM.H., PetersenL.J.. Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review.Cancer Treat Rev.2012; 38(2): 164–171.
74.
HicsonmezA., KucukO.N., AndrieuM.N.. Role of radionuclide therapy as adjuvant to palliative external beam radiotherapy for painful multiple skeletal metastasis.World J Oncol.2010; 1(4): 158–166.
75.
PorterA.T., McEwanA.J.. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.Semin Oncol.1993; 20(3 suppl 2): 38–43.
76.
SmelandS., EriksteinB., AasM.. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study.Int J Radiat Oncol Biol Phys.2003; 56(5): 1397–1404.
77.
LamM.G., DahmaneA., StevensW.H.. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.Eur J Nucl Med Mol Imaging.2008; 35(4): 756–765.
78.
RoquéI, FigulsM., Martinez-ZapataM.J.. Radioisotopes for metastatic bone pain.Cochrane Database Syst Rev.2011; (7): CD003347.
